Tris Pharma, Inc. reported positive topline results from the ALLEVIATE-1 Phase 3 clinical trial for cebranopadol, a potential first-in-class oral dual-NMR agonist aimed at treating moderate-to-severe acute pain, demonstrating significant efficacy and a favorable safety profile.
Company Information
Company
Tris Pharma
Location
Monmouth Junction, New Jersey, United States
About
Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients’ needs in neuroscience and other therapeutic categories.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tris Pharma ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.